In vitro protein binding of propafenone in normal and uraemic human sera

[1]  G. Chan,et al.  Determination of 5-hydroxypropafenone in biological fluids by fused-silica capillary gas chromatography using electron-capture detection. , 1989, Journal of chromatography.

[2]  J. Kremer,et al.  Drug binding to human alpha-1-acid glycoprotein in health and disease. , 1988, Pharmacological reviews.

[3]  P. Dorian,et al.  Influence of Hepatic Dysfunction on the Pharmacokinetics of Propafenone , 1987, Journal of clinical pharmacology.

[4]  M. Schlepper.  Propafenone, a review of its profile. , 1987, European heart journal.

[5]  A. Gillis,et al.  Binding of antiarrhythmic drugs to purified human α1-acid glycoprotein , 1985 .

[6]  S. Connolly,et al.  Clinical pharmacology of propafenone. , 1983, Circulation.

[7]  J. Huang,et al.  Effect of altered disopyramide binding on its pharmacologic response in rabbits. , 1982, The Journal of pharmacology and experimental therapeutics.

[8]  P. Routledge,et al.  Diazepam and lidocaine plasma protein binding in renal disease , 1982, Clinical pharmacology and therapeutics.

[9]  G. Breithardt,et al.  Propafenone--a new antiarrhythmic drug. , 1980, European heart journal.

[10]  H. Kurz,et al.  Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. , 1977, Arzneimittel-Forschung.

[11]  D. Shand,et al.  Plasma binding and the affinity of propranolol for a beta receptor in man , 1976, Clinical pharmacology and therapeutics.

[12]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[13]  C M Metzler,et al.  Bioavailability--a problem in equivalence. , 1974, Biometrics.

[14]  H. Rosenthal.  A graphic method for the determination and presentation of binding parameters in a complex system. , 1967, Analytical biochemistry.

[15]  G. Chan,et al.  Determination of propafenone in biological fluids by fused-silica capillary gas chromatography using electron-capture detection. , 1987, Journal of chromatography.

[16]  A. Gillis,et al.  Binding of antiarrhythmic drugs to purified human alpha 1-acid glycoprotein. , 1985, Biochemical pharmacology.

[17]  G. Breithardt,et al.  Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. , 1984, The American journal of cardiology.

[18]  R H Levy,et al.  Rationale for Monitoring Free Drug Levels , 1984, Clinical pharmacokinetics.

[19]  B. Lown,et al.  Propafenone: noninvasive evaluation of efficacy. , 1984, The American journal of cardiology.

[20]  D. Roden,et al.  Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. , 1984, The American journal of cardiology.

[21]  J. Mackichan.  Pharmacokinetic Consequences of Drug Displacement from Blood and Tissue Proteins , 1984, Clinical pharmacokinetics.

[22]  M. Raschack,et al.  Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. , 1984, Arzneimittel-Forschung.

[23]  S. Fulton,et al.  Ultrafiltration vs Equilibrium Dialysis for Determination of Free Fraction , 1984, Clinical pharmacokinetics.

[24]  M. Hollmann,et al.  Pharmacokinetic and Metabolic Studies on Propafenone in Volunteers , 1983 .

[25]  F. Pedersen,et al.  Serum alpha-1-acid glycoprotein (orosomucoid) in uremic patients on hemodialysis. , 1982, Nephron.